Report cover image

Europe Gene Therapy Market - Industry Trends and Forecast to 2030

Publisher Data Bridge Market Research
Published Mar 01, 2023
Length 149 Pages
SKU # DAABD17862158

Description

Europe Gene Therapy Market - Industry Trends and Forecast to 2030

Europe Gene Therapy Market, By Vector Type (Viral Vector and Non-Viral Vector), Method (Ex-Vivo and In-Vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Disease, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research Institutes, and Others), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe) Industry Trends and Forecast to 2030.

Market Definition

Gene therapy is a medical strategy that addresses the underlying genetic issue to treat or prevent disease. Instead of drugs or surgery, gene therapy procedures allow doctors to treat a problem by changing a person's genetic composition. A select few disorders, including an eye condition called Leber congenital amaurosis and a muscle condition called spinal muscular atrophy, are being treated with gene therapy. To ensure that they will be secure and efficient, many other gene therapies are undergoing study. Medical professionals aim to apply the promising genome editing technique soon to cure human illnesses.

The ability to successfully transport a therapeutic gene to a target cell is the essential prerequisite for gene therapy to be successful. Once transported, that gene must go to the cell wall's nucleus, a model for making protein molecules. The protein then produces the principal therapeutic action. For instance, cell destruction might be used to treat tumors, whereas cell preservation might be used in the case of neurodegenerative illness. However, strict regulations and standards for the approval and commercialization of products are expected to restrain market growth.

Market Segmentation

The Europe gene therapy market is segmented into four notable segments: vector type, method, application, and end user.
• On the basis of vector type, the market is segmented into viral vector and non-viral vector
• On the basis of method, the market is segmented into ex-vivo and in-vivo
• On the basis of application, the market is segmented into oncological disorders, cardiovascular diseases, infectious diseases, rare diseases, neurological disorders, and other diseases
• On the basis of end user, the market is segmented into cancer institutes, hospitals, research institutes, and others

Market Players

Some major companies dealing in the Europe gene therapy market are:
• Biogen
• Kite Pharma
• Novartis AG
• Bristol-Myers Squibb Company
• Oxford Biomedica
• Amgen, Inc.
• Ferring B.V.
• Dendreon Pharmaceuticals LLC.
• Janssen Europe Services, LLC,
• uniQure NV.
• Spark Therapeutics, Inc.
• AGC Biologics.
• Orchard Therapeutics plc
• Mallinckrodt Pharmaceuticals
• Bluebird Bio Inc.
• Sibiono GeneTech Co. Ltd.
• AnGes, Inc.
• CHIESI Farmaceutici S.p.A.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

149 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Europe Gene Therapy Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Market End User Coverage Grid
2.8 Product Lifeline Curve
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel Analysis
4.2 Porter Five Analysis
5 Update On Germline Gene Therapy
5.1 Germline Gene Therapy
6 Europe Gene Therapy Market, Mo
6.1 Drivers
6.1.1 Novel Approaches To Gene Therapy
6.1.2 Increasing Prevalence Of Genetic Disorders
6.1.3 The Growing Investment By Biotechnology & Pharmaceutical Companies
6.1.4 Growing Demand For Personalized Medicine
6.2 Restraints
6.2.1 High Cost Of Gene Therapy
6.2.2 Ethical And Safety Concerns
6.2.3 Complexity Of Gene Therapy
6.3 Opportunities
6.3.1 Rise In Strategic Acquisition And Partnership Among Organizations
6.3.2 Rising Approval For Gene Therapy Products
6.4 Challenges
6.4.1 Stringent Regulations For Gene Therapy Products
6.4.2 Long-term Safety And Efficacy
7 Europe Gene Therapy Market, By Vector Type
7.1 Overview
7.2 Viral Vector
7.2.1 Adenovirus
7.2.2 Retrovirus
7.2.3 Lentivirus
7.2.4 Adeno-associated Virus
7.2.5 Vaccinia Virus
7.2.6 Herpes Simplex Virus
7.2.7 Others
7.3 Non-viral Vector
7.3.1 Lipofection
7.3.2 Injection Of Naked Dna
8 Europe Gene Therapy Market, By Method
8.1 Overview
8.2 Ex-vivo
8.3 In-vivo
9 Europe Gene Therapy Market, By Application
9.1 Overview
9.2 Oncological Disorders
9.3 Cardiovascular Diseases
9.4 Infectious Diseases
9.5 Rare Diseases
9.6 Nuerological Disorders
9.7 Other Diseases
10 Europe Gene Therapy Market, By End User
10.1 Overview
10.2 Cancer Institutes
10.3 Hospitals
10.4 Research Institutes
10.5 Others
11 Europe Gene Therapy Market, By Region
11.1 Europe
11.1.1 Germany
11.1.2 France
11.1.3 U.K.
11.1.4 Italy
11.1.5 Spain
11.1.6 Russia
11.1.7 Turkey
11.1.8 Netherlands
11.1.9 Belgium
11.1.10 Switzerland
11.1.11 Rest Of Europe
12 Europe Gene Therapy Market, Company Landscape
12.1 Company Share Analysis: Europe
13 Company Profiles
13.1 Biogen
13.1.1 Company Snapshot
13.1.2 Revenue Analysis
13.1.3 Company Share Analysis
13.1.4 Swot Analysis
13.1.5 Product Portfolio
13.1.6 Recent Development
13.2 Kite Pharma
13.2.1 Company Snapshot
13.2.2 Revenue Analysis
13.2.3 Company Share Analysis
13.2.4 Swot Analysis
13.2.5 Product Portfolio
13.2.6 Recent Development
13.3 Novartis Ag
13.3.1 Company Snapshot
13.3.2 Revenue Analysis
13.3.3 Company Share Analysis
13.3.4 Swot Analysis
13.3.5 Product Portfolio
13.3.6 Recent Developments
13.4 Bristol-myers Squibb Company.
13.4.1 Company Snapshot
13.4.2 Revenue Analysis
13.4.3 Company Share Analysis
13.4.4 Swot Analysis
13.4.5 Product Portfolio
13.4.6 Recent Development
13.5 Oxford Biomedica
13.5.1 Company Snapshot
13.5.2 Revenue Analysis
13.5.3 Company Share Analysis
13.5.4 Swot Analysis
13.5.5 Product Portfolio
13.5.6 Recent Developments
13.6 Agc Biologics
13.6.1 Company Snapshot
13.6.2 Product Portfolio
13.6.3 Recent Development
13.7 Anges, Inc
13.7.1 Company Snapshot
13.7.2 Revenue Analysis
13.7.3 Product Portfolio
13.7.4 Recent Development
13.8 Amgen Inc.
13.8.1 Company Snapshot
13.8.2 Revenue Analysis
13.8.3 Product Portfolio
13.8.4 Recent Development
13.9 Bluebird Bio, Inc.
13.9.1 Company Snapshot
13.9.2 Product Portfolio
13.9.3 Recent Development
13.10 Chiesi Farmaceutici S.P.A
13.10.1 Company Snapshot
13.10.2 Revenue Analysis
13.10.3 Product Portfolio
13.10.4 Recent Development
13.11 Dendreon Pharmaceuticals Llc
13.11.1 Company Snapshot
13.11.2 Product Portfolio
13.11.3 Recent Development
13.12 Enzyvant Therapeutics Gmbh
13.12.1 Company Snapshot
13.12.2 Roduct Portfolio
13.12.3 Recent Development
13.13 Ferring B.V.
13.13.1 Company Snapshot
13.13.2 Product Portfolio
13.13.3 Recent Development
13.14 Janssen Pharmaceuticals, Inc.
13.14.1 Company Snapshot
13.14.2 Product Portfolio
13.14.3 Recent Development
13.15 Mallinckrodt.
13.15.1 Company Snapshot
13.15.2 Revenue Analysis
13.15.3 Product Portfolio
13.15.4 Recent Development
13.16 Orchard Therapeutics Plc.
13.16.1 Company Snapshot
13.16.2 Revenue Analysis
13.16.3 Product Portfolio
13.16.4 Recent Development
13.17 Shanghai Sunway Biotech Co., Ltd.
13.17.1 Company Snapshot
13.17.2 Product Portfolio
13.17.3 Recent Development
13.18 Sibono
13.18.1 Company Snapshot
13.18.2 Product Portfolio
13.18.3 Recent Development
13.19 Spark Therapeutics, Inc.
13.19.1 Company Snapshot
13.19.2 Product Portfolio
13.19.3 Recent Development
13.20 Uniqure Nv.
13.20.1 Company Snapshot
13.20.2 Revenue Analysis
13.20.3 Product Portfolio
13.20.4 Recent Development
14 Questionnaire
15 Related Reports 149
List Of Tables
Table 1 Europe Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 2 Europe Viral Vector In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 3 Europe Viral Vector In Gene Therapy Market, By Type, 2021-2030 (Usd Million)
Table 4 Europe Non-viral Vector In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 5 Europe Non-viral Vector In Gene Therapy Market, By Type, 2021-2030 (Usd Million)
Table 6 Europe Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 7 Europe Ex-vivo In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 8 Europe In –vivo In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 9 Europe Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 10 Europe Oncological Disorders In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 11 Europe Cardiovascular Diseases In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 12 Europe Infectious Diseases In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 13 Europe Rare Diseases In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 14 Europe Neurological Disorders In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 15 Europe Other Diseases In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 16 Europe Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 17 Europe Cancer Institutes In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 18 Europe Hospitals In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 19 Europe Research Institutes In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 20 Europe Others In Gene Therapy Market, By Region, 2021-2030 (Usd Million)
Table 21 Europe Gene Therapy Market, By Country, 2021-2030 (Usd Million)
Table 22 Europe Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 23 Europe Viral Vector In Gene Therapy Market, By Type, 2021-2030 (Usd Million)
Table 24 Europe Non-viral Vector In Gene Therapy Market, By Type, 2021-2030 (Usd Million)
Table 25 Europe Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 26 Europe Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 27 Europe Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 28 Germany Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 29 Germany Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 30 Germany Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 31 Germany Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 32 Germany Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 33 Germany Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 34 France Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 35 France Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 36 France Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 37 France Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 38 France Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 39 France Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 40 U.K. Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 41 U.K. Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 42 U.K. Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 43 U.K. Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 44 U.K. Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 45 U.K. Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 46 Italy Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 47 Italy Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 48 Italy Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 49 Italy Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 50 Italy Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 51 Italy Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 52 Spain Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 53 Spain Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 54 Spain Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 55 Spain Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 56 Spain Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 57 Spain Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 58 Russia Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 59 Russia Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 60 Russia Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 61 Russia Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 62 Russia Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 63 Russia Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 64 Turkey Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 65 Turkey Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 66 Turkey Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 67 Turkey Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 68 Turkey Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 69 Turkey Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 70 Netherlands Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 71 Netherlands Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 72 Netherlands Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 73 Netherlands Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 74 Netherlands Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 75 Netherlands Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 76 Belgium Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 77 Belgium Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 78 Belgium Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 79 Belgium Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 80 Belgium Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 81 Belgium Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 82 Switzerland Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 83 Switzerland Viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 84 Switzerland Non-viral Vector In Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
Table 85 Switzerland Gene Therapy Market, By Method, 2021-2030 (Usd Million)
Table 86 Switzerland Gene Therapy Market, By Application, 2021-2030 (Usd Million)
Table 87 Switzerland Gene Therapy Market, By End User, 2021-2030 (Usd Million)
Table 88 Rest Of Europe Gene Therapy Market, By Vector Type, 2021-2030 (Usd Million)
List Of Figures
Figure 1 Europe Gene Therapy Market: Segmentation
Figure 2 Europe Gene Therapy Market: Data Triangulation
Figure 3 Europe Gene Therapy Market: Droc Analysis
Figure 4 Europe Gene Therapy Market: Europe Vs Regional Market Analysis
Figure 5 Europe Gene Therapy Market: Company Research Analysis
Figure 6 Europe Gene Therapy Market: Interview Demographics
Figure 7 Europe Gene Therapy Market: Market End User Coverage Grid
Figure 8 Europe Gene Therapy Market: Dbmr Market Position Grid
Figure 9 Europe Gene Therapy Market: Vendor Share Analysis
Figure 10 Europe Gene Therapy Market: Segmentation
Figure 11 The Increasing Prevalence Of Genetic Disorders And Growing Demand For Personalized Medicine Are Expected To Drive The Growth Of The Europe Gene Therapy Market From 2023 To 2030
Figure 12 The Viral Vector Segment Is Expected To Account For The Largest Share Of The Europe Gene Therapy Market In 2023 & 2030
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Europe Gene Therapy Market
Figure 14 Europe Gene Therapy Market: By Vector Type, 2022
Figure 15 Europe Gene Therapy Market: By Vector Type, 2023-2030 (Usd Million)
Figure 16 Europe Gene Therapy Market: By Vector Type, Cagr (2023-2030)
Figure 17 Europe Gene Therapy Market: By Vector Type, Lifeline Curve
Figure 18 Europe Gene Therapy Market: By Method, 2022
Figure 19 Europe Gene Therapy Market: By Method, 2023-2030 (Usd Million)
Figure 20 Europe Gene Therapy Market: By Method, Cagr (2023-2030)
Figure 21 Europe Gene Therapy Market: By Method, Lifeline Curve
Figure 22 Europe Gene Therapy Market: By Application, 2022
Figure 23 Europe Gene Therapy Market: By Application, 2023-2030 (Usd Million)
Figure 24 Europe Gene Therapy Market: By Application, Cagr (2023-2030)
Figure 25 Europe Gene Therapy Market: By Application, Lifeline Curve
Figure 26 Europe Gene Therapy Market: By End User, 2022
Figure 27 Europe Gene Therapy Market: By End User, 2023-2030 (Usd Million)
Figure 28 Europe Gene Therapy Market: By End User, Cagr (2023-2030)
Figure 29 Europe Gene Therapy Market: By End User, Lifeline Curve
Figure 30 Europe Gene Therapy Market: Snapshot (2022)
Figure 31 Europe Gene Therapy Market: By Country (2022)
Figure 32 Europe Gene Therapy Market: By Country (2023 & 2030)
Figure 33 Europe Gene Therapy Market: By Country (2022 & 2030)
Figure 34 Europe Gene Therapy Market: Vector Type (2023-2030)
Figure 35 Europe Gene Therapy Market: Company Share 2022 (%) 103

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us